ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy

ClinicalTrials.gov ID: NCT06797869

Public ClinicalTrials.gov record NCT06797869. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 7, 2026, 12:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Efficacy and Safety of co Administered Cagrilintide and Semaglutide (CagriSema) Once Weekly Versus Placebo in Participants With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy

Study identification

NCT ID
NCT06797869
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
142 participants

Conditions and interventions

Interventions

  • CagriSema (Cagrilintide B and Semaglutide I) Drug
  • Placebo matched to CagriSema (Cagrilintide B and Semaglutide I) Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 28, 2025
Primary completion
Aug 20, 2026
Completion
Aug 20, 2026
Last update posted
Dec 4, 2025

2025 – 2026

United States locations

U.S. sites
19
U.S. states
13
U.S. cities
17
Facility City State ZIP Site status
eStudySite La Mesa California 91942
Linda Vista Health Care Ctr San Diego California 92111
My Preferred Research Miami Florida 33155
New Horizon Research Center Miami Florida 33165
Renstar Medical Research Ocala Florida 34471
Foot & Ankle Center of Illinois Springfield Illinois 62704
Velocity Clinical Research Rockville Rockville Maryland 20854
Amicis Centers of Clinical Research St Louis Missouri 63128
DM Clinical - CyFair Albuquerque New Mexico 87106
Southgate Medical Group, LLP West Seneca New York 14224
Piedmont Healthcare/Research Statesville North Carolina 28625
Lillestol Research LLC Fargo North Dakota 58104
Oregon Health & Science University Portland Oregon 97239
Clinical Res Collaborative Cumberland Rhode Island 02864
DM Clinical - CyFair Houston Texas 77081
Radiance Clinical Research Lampasas Texas 76550
DM Clinical - CyFair San Antonio Texas 78207
DM Clinical Research San Antonio Texas 78207
Velocity Clinical Research Portsmouth Suffolk Virginia 23435

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 35 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06797869, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 4, 2025 · Synced May 7, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06797869 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →